Wellington Management Group LLP Has $1.62 Billion Position in Edwards Lifesciences Corporation $EW

Wellington Management Group LLP grew its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 4.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 20,804,416 shares of the medical research company’s stock after purchasing an additional 977,933 shares during the quarter. Wellington Management Group LLP’s holdings in Edwards Lifesciences were worth $1,617,959,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Norges Bank acquired a new position in shares of Edwards Lifesciences in the second quarter valued at approximately $580,640,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its position in Edwards Lifesciences by 111.2% during the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company’s stock worth $714,006,000 after buying an additional 4,805,819 shares during the period. Marshall Wace LLP boosted its position in Edwards Lifesciences by 127.5% during the 2nd quarter. Marshall Wace LLP now owns 6,895,579 shares of the medical research company’s stock worth $539,303,000 after buying an additional 3,864,908 shares during the period. Jennison Associates LLC grew its holdings in Edwards Lifesciences by 19.6% during the 3rd quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company’s stock worth $1,085,574,000 after acquiring an additional 2,287,783 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in Edwards Lifesciences by 8.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company’s stock valued at $1,478,425,000 after acquiring an additional 1,423,365 shares during the period. 79.46% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CFO Scott B. Ullem sold 13,000 shares of the company’s stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $84.92, for a total value of $1,103,960.00. Following the sale, the chief financial officer owned 39,699 shares in the company, valued at $3,371,239.08. This represents a 24.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Daniel J. Lippis sold 1,019 shares of the firm’s stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $85.38, for a total transaction of $87,002.22. Following the completion of the transaction, the vice president directly owned 33,934 shares in the company, valued at approximately $2,897,284.92. The trade was a 2.92% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 61,718 shares of company stock worth $5,236,281 in the last quarter. Insiders own 1.29% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on EW shares. Royal Bank Of Canada lifted their price target on shares of Edwards Lifesciences from $95.00 to $100.00 and gave the stock an “outperform” rating in a report on Friday, December 5th. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Wednesday, January 21st. Stifel Nicolaus set a $110.00 target price on Edwards Lifesciences and gave the stock a “buy” rating in a research report on Tuesday, January 20th. Barclays reiterated an “overweight” rating and issued a $104.00 price target (up from $103.00) on shares of Edwards Lifesciences in a research report on Monday, January 12th. Finally, Evercore reissued an “outperform” rating and issued a $94.00 price target on shares of Edwards Lifesciences in a research note on Monday, January 5th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $96.14.

Edwards Lifesciences Price Performance

Shares of EW opened at $81.82 on Friday. The firm has a market cap of $47.52 billion, a PE ratio of 44.71, a price-to-earnings-growth ratio of 2.21 and a beta of 0.93. Edwards Lifesciences Corporation has a 52-week low of $65.94 and a 52-week high of $87.89. The business’s 50 day moving average price is $82.41 and its two-hundred day moving average price is $81.58. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.09 and a current ratio of 3.72.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.04). The company had revenue of $1.57 billion for the quarter, compared to analyst estimates of $1.54 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. Edwards Lifesciences’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.59 EPS. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, equities analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.